shutterstock_1572740566_nitpicker
nitpicker / Shutterstock.com
13 April 2021Big PharmaRory O'Neill

Sanofi and C4X in $493m licensing deal

UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million ($493 million), which will see the French pharmaceutical company develop anti-inflammatory therapies.

Most of the potential windfall for C4X is based on development, regulatory, and commercialisation milestones, with the UK company receiving €7 million upfront. The deal also includes €11 million in potential pre-clinical milestone payments.

The agreement gives Sanofi exclusive access to C4X’s IL-17A inhibitor programme. IL-17 cytokines are “strong inducers of inflammation” and linked to autoimmune diseases including psoriasis, the UK company said. Sanofi will look to develop oral small-molecule treatments for such conditions based on C4X’s IL-17 inhibitors, providing an alternative to available antibody drugs, which are administered via an injection.

“We are proud to be working with Sanofi to create much needed oral therapies in the underserved inflammatory disease space. While antibody therapies have demonstrated the potential of IL-17 inhibition in the generation of highly effective treatments, the injectable route means many patients currently do not have access to the medicines that can change their lives,” said Clive Dix, C4X CEO.

We believe that our small molecule programme has the potential to create high value, efficacious and convenient oral IL-17 therapeutics for this large market,” Dix added.

The C4X CEO, who also serves as chair of the UK’s vaccine taskforce, described the Sanofi deal as the “second significant agreement for a C4XD programme”, and a “major milestone” for the company.

In 2018, C4X agreed an exclusive licensing deal with Indivior, which is currently developing a molecule to treat opioid addiction using C4X’s programme. The drug candidate is currently in a phase 1 clinical trial.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

More on this story

Medtech
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

More on this story

Medtech
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Americas
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.